Cancer/Oncology

illumiSonics Inc. Expands Its Executive Management With the Appointment of Jochen Schweizer as Chief Operating Officer

by

illumiSonics Inc., a medical tissue imaging company, announced today the appointment of Jochen Schweizer as COO. The company is further strengthening the executive team as they commercialize their cancer detection and diagnostics products using the proprietary PARS imaging platform technology. Mr. Schweizer previously held executive positions at Danaher/Leica, responsible for the Microsurgery Portfolio in the business … Read more

illumiSonics Inc. Expands Its Executive Management With the Appointment of Jochen Schweizer as Chief Operating Officer

by

illumiSonics Inc., a medical tissue imaging company, announced today the appointment of Jochen Schweizer as COO.  The company is further strengthening the executive team as they commercialize their Cancer detection and diagnostics products using the proprietary PARS imaging platform technology. Mr. Schweizer previously held executive positions at Danaher/Leica, responsible for the Microsurgery Portfolio in the business … Read more

illumiSonics Inc. Expands Its Executive Management With the Appointment of Jochen Schweizer as Chief Operating Officer

by

illumiSonics Inc., a medical tissue imaging company, announced today the appointment of Jochen Schweizer as COO. The company is further strengthening the executive team as they commercialize their cancer detection and diagnostics products using the proprietary PARS imaging platform technology. Mr. Schweizer previously held executive positions at Danaher/Leica, responsible for the Microsurgery Portfolio in the business … Read more

Curesponse Secures Additional USD 8 Million Funding for Its Breakthrough Precision Oncology Platform

by

Curesponse (www.curesponse.com) has secured additional USD 8 million funding for its breakthrough precision oncology platform. Curesponse is a cancer precision medicine company whose platform, cResponse, accurately and timely predicts a patient’s response to cancer treatment. The company has raised an additional USD 8 million from leading investors to facilitate scaling of clinical studies and expansion of commercial international … Read more

CytoImmune Therapeutics Appoints Renowned Oncologist and Immunologist as New Chief Executive Officer

by

CytoImmune Therapeutics, a privately-held cell therapy company focused on developing natural killer (NK) immune cells to fight cancer, announces the appointment of Christina Coughlin M.D., Ph.D., as their Chief Executive Officer. Dr. Coughlin will provide strategic leadership for the recently launched biotech and its clinical-stage pipeline of engineered NK cell therapies designed to improve outcomes … Read more

3-Year Global MPN Interferon Initiative Report Released by MPN Research Foundation

by

In real-world usage and in clinical trials, interferon (IFN) in a variety of forms has shown high rates of hematologic and molecular responses in many patients with rare blood cancers known as myeloproliferative neoplasms (MPNs). Other patients have no significant response, and some develop drug resistance to recombinant interferon over time. A report summarizing a three-year … Read more

The MDS Foundation Celebrates MDS World Awareness Day With Their 4th Annual Move for MDS 5k Walk at Boston Common and Virtually Around the World

by

The MDS Foundation, a global non-profit advocacy organization is proud to announce its fourth annual Move for MDS walk at Boston Common on Sunday, Oct. 24. Additionally, teams and individuals from around the globe will run, walk or wheel virtually to drive awareness and accelerate research for Myelodysplastic Syndromes (MDS), a rare blood cancer. Each year, up to 20k new MDS … Read more

Jubilant Radiopharma Announces Eckert & Ziegler’s GalliaPharm® Approved for Use With NETSPOT in Canada

by

On June 30, 2021, Health Canada approved Eckert & Ziegler Radiopharma’s GalliaPharm® Ge68/Ga-68 generator for use with Advance Accelerator Systems’ NETSpot kit used for the localization of somatostatin receptor positive neuroendocrine tumors (NET) in adult patients using Positron Emission Tomography (PET). “NETSPOT® is the only registered Ga-68 based radiopharmaceutical in Canada,” explained Dr. Harald Hasselmann, Eckert … Read more

The Quality Cancer Care Alliance Adds Cancer Center of Middle Georgia (CCMG) to Its National Network

by

Continuing its expansion across the country, Quality Cancer Care Alliance Network (QCCAN) is delighted to announce the addition of the Cancer Center of Middle Georgia (CCMG) to its network of independently owned and operated oncology and hematology practices located across the United States. The Cancer Center of Middle Georgia started with a vision to have … Read more

This National Cancer Survivor Month, cCARE Celebrates All Survivors and Those Helped by Its Survivorship Care Initiative

by

Every day through its Survivorship Care efforts, cCARE supports and celebrates cancer survivors like Susan Webster, who beat breast cancer and now runs a nonprofit fitness program for cancer survivors. Though many people view cancer through a lens of fear and sorrow, cCARE, the largest full-service private oncology practice in California, sees National Cancer Survivor … Read more